{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:07:38Z","timestamp":1788944858832,"version":"build-2803163510"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"General Project of Natural Science Foundation of Liaoning Provincial Department of Science and Technology","award":["No.2022-MS-09"],"award-info":[{"award-number":["No.2022-MS-09"]}]},{"name":"General Project of Natural Science Foundation of Xizang Provincial Department of Science and Technology","award":["No.XZ2021R-ZY46(Z)"],"award-info":[{"award-number":["No.XZ2021R-ZY46(Z)"]}]},{"name":"General Project of the Natural Science Foundation of Liaoning Provincial Department of Science and Technology","award":["No. 2025-MS- 233"],"award-info":[{"award-number":["No. 2025-MS- 233"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The combination of radiation therapy and immunotherapy has become a cornerstone of modern clinical cancer treatment. However, the inherent radiation resistance of tumors and complex immune evasion mechanisms remain major bottlenecks limiting their long-term effects and sustained efficacy. E3 ubiquitin ligases critically influence tumor sensitivity to radioimmunotherapy by controlling protein stability across DNA repair, immune signaling, and stress-response pathways. This review systematically dissects the multidimensional molecular network through which E3 ubiquitin ligases regulate radiosensitivity and immunoresponsiveness. At the intracellular level, we provide an in-depth analysis of how E3 ubiquitin ligases determine the fate of radiation-induced damage repair by precisely regulating the kinetics of the DNA damage response (DDR), cell cycle checkpoints, and apoptosis thresholds. At the extracellular level, this study focuses on the key roles of E3 ubiquitin ligases in reshaping the immune microenvironment, including the maintenance of spatiotemporal stability of immune checkpoints, the fidelity of antigen processing and presentation, and the epigenetic regulation of microenvironmental dynamic plasticity. Recent studies indicate that E3 ubiquitin ligases link radiation-induced DDR signaling to innate and adaptive immune activation, particularly through the induction of immunogenic cell death (ICD) and the calibration of innate immune sensing pathways like cGAS-STING. Finally, we provide a comprehensive synthesis of cutting-edge translational strategies targeting E3 ubiquitin ligases\u2014ranging from canonical inhibitors to transformative proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs)\u2014offering novel paradigms for overcoming therapeutic resistance and refining personalized radioimmunotherapy.<\/jats:p>","DOI":"10.1186\/s12943-026-02739-x","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:17:01Z","timestamp":1784733421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting E3 ubiquitin ligases: Mechanistic breakthroughs and novel clinical translation pathways for tumor radioimmunotherapy"],"prefix":"10.1186","volume":"25","author":[{"given":"Qian","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinruo","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"2739_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"R-X Huang","year":"2020","unstructured":"Huang R-X, Zhou P-K. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020;5:60. https:\/\/doi.org\/10.1038\/s41392-020-0150-x.","journal-title":"Signal Transduct Target Ther"},{"key":"2739_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.radonc.2020.09.005","volume":"154","author":"S Zheng","year":"2021","unstructured":"Zheng S, Wu Y, Li Z. Integrating cullin2-RING E3 ligase as a potential biomarker for glioblastoma multiforme prognosis and radiosensitivity profiling. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2021;154:36\u201344. https:\/\/doi.org\/10.1016\/j.radonc.2020.09.005.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"2739_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175\u201396. https:\/\/doi.org\/10.1038\/s41573-018-0006-z.","journal-title":"Nat Rev Drug Discov"},{"key":"2739_CR4","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science. 2011;331:1565\u201370. https:\/\/doi.org\/10.1126\/science.1203486.","journal-title":"Science"},{"key":"2739_CR5","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3389\/fonc.2019.01259","volume":"9","author":"Y-S Seo","year":"2019","unstructured":"Seo Y-S, Ko IO, Park H, Jeong YJ, Park J-A, Kim KS, et al. Radiation-Induced Changes in Tumor Vessels and Microenvironment Contribute to Therapeutic Resistance in Glioblastoma. Front Oncol. 2019;9:1259. https:\/\/doi.org\/10.3389\/fonc.2019.01259.","journal-title":"Front Oncol"},{"key":"2739_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0167-8140(94)90408-1","volume":"31","author":"A Maity","year":"1994","unstructured":"Maity A, McKenna WG, Muschel RJ. The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol J Eur Soc Ther Radiol Oncol. 1994;31:1\u201313. https:\/\/doi.org\/10.1016\/0167-8140(94)90408-1.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"2739_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrc776","volume":"2","author":"FH Igney","year":"2002","unstructured":"Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277\u201388. https:\/\/doi.org\/10.1038\/nrc776.","journal-title":"Nat Rev Cancer"},{"key":"2739_CR8","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1667\/RR2295.1","volume":"174","author":"N Lynam-Lennon","year":"2010","unstructured":"Lynam-Lennon N, Reynolds JV, Pidgeon GP, Lysaght J, Marignol L, Maher SG. Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma. Radiat Res. 2010;174:703\u201311. https:\/\/doi.org\/10.1667\/RR2295.1.","journal-title":"Radiat Res"},{"key":"2739_CR9","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol. 2023;14:1212476. https:\/\/doi.org\/10.3389\/fimmu.2023.1212476.","journal-title":"Front Immunol"},{"key":"2739_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nrc1994","volume":"6","author":"D Hoeller","year":"2006","unstructured":"Hoeller D, Hecker C-M, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer. 2006;6:776\u201388. https:\/\/doi.org\/10.1038\/nrc1994.","journal-title":"Nat Rev Cancer"},{"key":"2739_CR11","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrm.2016.91","volume":"17","author":"L Buetow","year":"2016","unstructured":"Buetow L, Huang DT. Structural insights into the catalysis and regulation of E3 ubiquitin ligases. Nat Rev Mol Cell Biol. 2016;17:626\u201342. https:\/\/doi.org\/10.1038\/nrm.2016.91.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2739_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00109-020-02015-5","volume":"99","author":"H Wang","year":"2021","unstructured":"Wang H, Lu Y, Wang M, Wu Y, Wang X, Li Y. Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance. J Mol Med Berl Ger. 2021;99:193\u2013212. https:\/\/doi.org\/10.1007\/s00109-020-02015-5.","journal-title":"J Mol Med Berl Ger"},{"key":"2739_CR13","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.3390\/biomedicines11123240","volume":"11","author":"M Zhang","year":"2023","unstructured":"Zhang M, Shao Y, Gu W. The Mechanism of Ubiquitination or Deubiquitination Modifications in Regulating Solid Tumor Radiosensitivity. Biomedicines. 2023;11:3240. https:\/\/doi.org\/10.3390\/biomedicines11123240.","journal-title":"Biomedicines"},{"key":"2739_CR14","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1002\/mco2.388","volume":"4","author":"J Tan","year":"2023","unstructured":"Tan J, Sun X, Zhao H, Guan H, Gao S, Zhou P-K. Double-strand DNA break repair: molecular mechanisms and therapeutic targets. MedComm. 2023;4:e388. https:\/\/doi.org\/10.1002\/mco2.388.","journal-title":"MedComm"},{"key":"2739_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.molcel.2013.11.003","volume":"53","author":"A Shibata","year":"2014","unstructured":"Shibata A, Moiani D, Arvai AS, Perry J, Harding SM, Genois M-M, et al. DNA double-strand break repair pathway choice is directed by distinct MRE11 nuclease activities. Mol Cell. 2014;53:7\u201318. https:\/\/doi.org\/10.1016\/j.molcel.2013.11.003.","journal-title":"Mol Cell"},{"key":"2739_CR16","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1158\/0008-5472.CAN-16-3232","volume":"77","author":"J Nicholson","year":"2017","unstructured":"Nicholson J, Jevons SJ, Groselj B, Ellermann S, Konietzny R, Kerr M, et al. E3 Ligase cIAP2 Mediates Downregulation of MRE11 and Radiosensitization in Response to HDAC Inhibition in Bladder Cancer. Cancer Res. 2017;77:3027\u201339. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-3232.","journal-title":"Cancer Res"},{"key":"2739_CR17","doi-asserted-by":"publisher","first-page":"e2203884","DOI":"10.1002\/advs.202203884","volume":"10","author":"W Liu","year":"2023","unstructured":"Liu W, Zheng M, Zhang R, Jiang Q, Du G, Wu Y, et al. RNF126-Mediated MRE11 Ubiquitination Activates the DNA Damage Response and Confers Resistance of Triple-Negative Breast Cancer to Radiotherapy. Adv Sci Weinh Baden-Wurtt Ger. 2023;10:e2203884. https:\/\/doi.org\/10.1002\/advs.202203884.","journal-title":"Adv Sci Weinh Baden-Wurtt Ger"},{"key":"2739_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/embj.201386064","volume":"33","author":"Q Wang","year":"2014","unstructured":"Wang Q, Goldstein M, Alexander P, Wakeman TP, Sun T, Feng J, et al. Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular response to DNA double-strand breaks. EMBO J. 2014;33:862\u201377. https:\/\/doi.org\/10.1002\/embj.201386064.","journal-title":"EMBO J"},{"key":"2739_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.radonc.2013.06.021","volume":"108","author":"B Groselj","year":"2013","unstructured":"Groselj B, Kerr M, Kiltie AE. Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2013;108:429\u201333. https:\/\/doi.org\/10.1016\/j.radonc.2013.06.021.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"2739_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3109\/09553002.2011.530335","volume":"87","author":"X Li","year":"2011","unstructured":"Li X, Meng Q, Rosen EM, Fan S. UHRF1 confers radioresistance to human breast cancer cells. Int J Radiat Biol. 2011;87:263\u201373. https:\/\/doi.org\/10.3109\/09553002.2011.530335.","journal-title":"Int J Radiat Biol"},{"key":"2739_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nsmb.2078","volume":"18","author":"J Wu","year":"2011","unstructured":"Wu J, Chen Y, Lu L-Y, Wu Y, Paulsen MT, Ljungman M, et al. Chfr and RNF8 synergistically regulate ATM activation. Nat Struct Mol Biol. 2011;18:761\u20138. https:\/\/doi.org\/10.1038\/nsmb.2078.","journal-title":"Nat Struct Mol Biol"},{"key":"2739_CR22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrm2514","volume":"9","author":"MF Lavin","year":"2008","unstructured":"Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol. 2008;9:759\u201369. https:\/\/doi.org\/10.1038\/nrm2514.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2739_CR23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/cells11030356","volume":"11","author":"MGM Khan","year":"2022","unstructured":"Khan MGM, Wang Y. Advances in the Current Understanding of How Low-Dose Radiation Affects the Cell Cycle. Cells. 2022;11:356. https:\/\/doi.org\/10.3390\/cells11030356.","journal-title":"Cells"},{"key":"2739_CR24","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1007\/s12035-022-02868-6","volume":"59","author":"S Xie","year":"2022","unstructured":"Xie S, Hong Z, Li Y, Wang J, Wang J, Li S, et al. RNF216 Alleviates Radiation-Induced Apoptosis and DNA Damage Through Regulating Ubiquitination-Mediated Degradation of p53 in Glioblastoma. Mol Neurobiol. 2022;59:4703\u201317. https:\/\/doi.org\/10.1007\/s12035-022-02868-6.","journal-title":"Mol Neurobiol"},{"key":"2739_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.lungcan.2013.04.017","volume":"81","author":"H Luo","year":"2013","unstructured":"Luo H, Yount C, Lang H, Yang A, Riemer EC, Lyons K, et al. Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence. Lung Cancer Amst Neth. 2013;81:167\u201373. https:\/\/doi.org\/10.1016\/j.lungcan.2013.04.017.","journal-title":"Lung Cancer Amst Neth"},{"key":"2739_CR26","first-page":"1279","volume":"62","author":"C Wiese","year":"2002","unstructured":"Wiese C, Pierce AJ, Gauny SS, Jasin M, Kronenberg A. Gene conversion is strongly induced in human cells by double-strand breaks and is modulated by the expression of BCL-x(L). Cancer Res. 2002;62:1279\u201383.","journal-title":"Cancer Res"},{"key":"2739_CR27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41419-023-05637-y","volume":"14","author":"X Dong","year":"2023","unstructured":"Dong X, Li X, Gan Y, Ding J, Wei B, Zhou L, et al. TRAF4-mediated ubiquitination-dependent activation of JNK\/Bcl-xL drives radioresistance. Cell Death Dis. 2023;14:102. https:\/\/doi.org\/10.1038\/s41419-023-05637-y.","journal-title":"Cell Death Dis"},{"key":"2739_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","volume":"9","author":"SJ Wang","year":"2023","unstructured":"Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer. 2023;9:543\u201353. https:\/\/doi.org\/10.1016\/j.trecan.2023.04.002.","journal-title":"Trends Cancer"},{"key":"2739_CR29","doi-asserted-by":"publisher","first-page":"101480","DOI":"10.1016\/j.smim.2021.101480","volume":"52","author":"KE Pauken","year":"2021","unstructured":"Pauken KE, Torchia JA, Chaudhri A, Sharpe AH, Freeman GJ. Emerging concepts in PD-1 checkpoint biology. Semin Immunol. 2021;52:101480. https:\/\/doi.org\/10.1016\/j.smim.2021.101480.","journal-title":"Semin Immunol"},{"key":"2739_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","volume":"82","author":"W Jing","year":"2022","unstructured":"Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, et al. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance. Cancer Res. 2022;82:114\u201329. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-2362.","journal-title":"Cancer Res"},{"key":"2739_CR31","doi-asserted-by":"publisher","first-page":"ra95","DOI":"10.1126\/scisignal.2005290","volume":"7","author":"A Persaud","year":"2014","unstructured":"Persaud A, Alberts P, Mari S, Tong J, Murchie R, Maspero E, et al. Tyrosine phosphorylation of NEDD4 activates its ubiquitin ligase activity. Sci Signal. 2014;7:ra95. https:\/\/doi.org\/10.1126\/scisignal.2005290.","journal-title":"Sci Signal"},{"key":"2739_CR32","doi-asserted-by":"publisher","first-page":"e006007","DOI":"10.1136\/jitc-2022-006007","volume":"11","author":"RC Augustin","year":"2023","unstructured":"Augustin RC, Bao R, Luke JJ. Targeting Cbl-b in cancer immunotherapy. J Immunother Cancer. 2023;11:e006007. https:\/\/doi.org\/10.1136\/jitc-2022-006007.","journal-title":"J Immunother Cancer"},{"key":"2739_CR33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41590-019-0400-7","volume":"20","author":"Q Hu","year":"2019","unstructured":"Hu Q, Ye Y, Chan L-C, Li Y, Liang K, Lin A, et al. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019;20:835\u201351. https:\/\/doi.org\/10.1038\/s41590-019-0400-7.","journal-title":"Nat Immunol"},{"key":"2739_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/nature10005","volume":"474","author":"AC Vitari","year":"2011","unstructured":"Vitari AC, Leong KG, Newton K, Yee C, O\u2019Rourke K, Liu J, et al. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature. 2011;474:403\u20136. https:\/\/doi.org\/10.1038\/nature10005.","journal-title":"Nature"},{"key":"2739_CR35","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1016\/j.cell.2021.09.006","volume":"184","author":"X Wang","year":"2021","unstructured":"Wang X, Tokheim C, Gu SS, Wang B, Tang Q, Li Y, et al. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell. 2021;184:5357\u2013e537422. https:\/\/doi.org\/10.1016\/j.cell.2021.09.006.","journal-title":"Cell"},{"key":"2739_CR36","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s10495-022-01738-9","volume":"27","author":"C Yu","year":"2022","unstructured":"Yu C, Xue B, Li J, Zhang Q. Tumor cell-derived exosome RNF126 affects the immune microenvironment and promotes nasopharyngeal carcinoma progression by regulating PTEN ubiquitination. Apoptosis Int J Program Cell Death. 2022;27:590\u2013605. https:\/\/doi.org\/10.1007\/s10495-022-01738-9.","journal-title":"Apoptosis Int J Program Cell Death"},{"key":"2739_CR37","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/jcmm.14063","volume":"23","author":"N Yu","year":"2019","unstructured":"Yu N, Xue M, Wang W, Xia D, Li Y, Zhou X, et al. RNF168 facilitates proliferation and invasion of esophageal carcinoma, possibly via stabilizing STAT1. J Cell Mol Med. 2019;23:1553\u201361. https:\/\/doi.org\/10.1111\/jcmm.14063.","journal-title":"J Cell Mol Med"},{"key":"2739_CR38","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.celrep.2014.12.021","volume":"10","author":"M Gatti","year":"2015","unstructured":"Gatti M, Pinato S, Maiolica A, Rocchio F, Prato MG, Aebersold R, et al. RNF168 promotes noncanonical K27 ubiquitination to signal DNA damage. Cell Rep. 2015;10:226\u201338. https:\/\/doi.org\/10.1016\/j.celrep.2014.12.021.","journal-title":"Cell Rep"},{"key":"2739_CR39","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2007.10.017","volume":"131","author":"Y-G Yang","year":"2007","unstructured":"Yang Y-G, Lindahl T, Barnes DE. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell. 2007;131:873\u201386. https:\/\/doi.org\/10.1016\/j.cell.2007.10.017.","journal-title":"Cell"},{"key":"2739_CR40","doi-asserted-by":"publisher","first-page":"5230","DOI":"10.1016\/j.cell.2021.08.035","volume":"184","author":"GP Nader","year":"2021","unstructured":"Nader GP, de F, Ag\u00fcera-Gonzalez S, Routet F, Gratia M, Maurin M, Cancila V, et al. Compromised nuclear envelope integrity drives TREX1-dependent DNA damage and tumor cell invasion. Cell. 2021;184:5230\u2013e524622. https:\/\/doi.org\/10.1016\/j.cell.2021.08.035.","journal-title":"Cell"},{"key":"2739_CR41","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-23-0700","volume":"14","author":"T Tani","year":"2024","unstructured":"Tani T, Mathsyaraja H, Campisi M, Li Z-H, Haratani K, Fahey CG, et al. TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity. Cancer Discov. 2024;14:752\u201365. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0700.","journal-title":"Cancer Discov"},{"key":"2739_CR42","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/s0360-3016(01)01609-1","volume":"51","author":"FG Barker","year":"2001","unstructured":"Barker FG, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;51:410\u20138. https:\/\/doi.org\/10.1016\/s0360-3016(01)01609-1.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2739_CR43","doi-asserted-by":"publisher","first-page":"113871","DOI":"10.1016\/j.ejmech.2021.113871","volume":"227","author":"X Xue","year":"2022","unstructured":"Xue X, Kang J-B, Yang X, Li N, Chang L, Ji J, et al. An efficient strategy for digging protein-protein interactions for rational drug design - A case study with HIF-1\u03b1\/VHL. Eur J Med Chem. 2022;227:113871. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113871.","journal-title":"Eur J Med Chem"},{"key":"2739_CR44","doi-asserted-by":"publisher","first-page":"17551","DOI":"10.1021\/acs.jmedchem.4c01549","volume":"67","author":"Y Chen","year":"2024","unstructured":"Chen Y, Zhang M, Liu Z, Zhang N, Wang Q. Ursodeoxycholic Acid Platinum(IV) Conjugates as Antiproliferative and Antimetastatic Agents: Remodel the Tumor Microenvironment through Suppressing JAK2\/STAT3 Signaling. J Med Chem. 2024;67:17551\u201367. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01549.","journal-title":"J Med Chem"},{"key":"2739_CR45","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1158\/0008-5472.CAN-25-2616","volume":"86","author":"L Kong","year":"2026","unstructured":"Kong L, Zhou M, Yuan W, Wang Y, Liu X, Wang J, et al. Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion. Cancer Res. 2026;86:1480\u201395. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-2616.","journal-title":"Cancer Res"},{"key":"2739_CR46","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41467-023-36523-y","volume":"14","author":"J-Y Li","year":"2023","unstructured":"Li J-Y, Zhao Y, Gong S, Wang M-M, Liu X, He Q-M, et al. TRIM21 inhibits irradiation-induced mitochondrial DNA release and impairs antitumour immunity in nasopharyngeal carcinoma tumour models. Nat Commun. 2023;14:865. https:\/\/doi.org\/10.1038\/s41467-023-36523-y.","journal-title":"Nat Commun"},{"key":"2739_CR47","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41419-022-05500-6","volume":"13","author":"M Li","year":"2022","unstructured":"Li M, Gao F, Li X, Gan Y, Han S, Yu X, et al. Stabilization of MCL-1 by E3 ligase TRAF4 confers radioresistance. Cell Death Dis. 2022;13:1053. https:\/\/doi.org\/10.1038\/s41419-022-05500-6.","journal-title":"Cell Death Dis"},{"key":"2739_CR48","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7150\/ijbs.87180","volume":"20","author":"J Liao","year":"2024","unstructured":"Liao J, Qing X, Li X, Gan Y, Wang R, Han S, et al. TRAF4 regulates ubiquitination-modulated survivin turnover and confers radioresistance. Int J Biol Sci. 2024;20:182\u201399. https:\/\/doi.org\/10.7150\/ijbs.87180.","journal-title":"Int J Biol Sci"},{"key":"2739_CR49","doi-asserted-by":"publisher","first-page":"124074","DOI":"10.1016\/j.biomaterials.2026.124074","volume":"330","author":"R Wang","year":"2026","unstructured":"Wang R, Yang X, Wong YH, Guo L, Wu C, Chan BP. PINCH-1-dependent regulation on tumor matrix microenvironment in pancreatic cancer. Biomaterials. 2026;330:124074. https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124074.","journal-title":"Biomaterials"},{"key":"2739_CR50","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/s42003-023-05667-4","volume":"6","author":"S Shen","year":"2023","unstructured":"Shen S, Liu X, Guo Q, Liang Q, Wu J, Guan G, et al. Tumor microenvironment remodeling plus immunotherapy could be used in mesenchymal-like tumor with high tumor residual and drug resistant rate. Commun Biol. 2023;6:1281. https:\/\/doi.org\/10.1038\/s42003-023-05667-4.","journal-title":"Commun Biol"},{"key":"2739_CR51","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3390\/cells11030405","volume":"11","author":"P Pandya","year":"2022","unstructured":"Pandya P, Kublo L, Stewart-Ornstein J. p53 Promotes Cytokine Expression in Melanoma to Regulate Drug Resistance and Migration. Cells. 2022;11:405. https:\/\/doi.org\/10.3390\/cells11030405.","journal-title":"Cells"},{"key":"2739_CR52","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-24-3628","volume":"31","author":"Z Nian","year":"2025","unstructured":"Nian Z, Dou Y, Wei H. p53: An Immune Ecosystem Manipulator. Clin Cancer Res. 2025;31:5120\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3628.","journal-title":"Clin Cancer Res"},{"key":"2739_CR53","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095.","journal-title":"Cancer Discov"},{"key":"2739_CR54","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41401-024-01394-6","volume":"46","author":"Q Hu","year":"2025","unstructured":"Hu Q, Li L, Li Y, Zhang H, Deng T, Liu Y, et al. A structure-based virtual screening identifies a novel MDM2 antagonist in the activation of the p53 signaling and inhibition of tumor growth. Acta Pharmacol Sin. 2025;46:740\u201350. https:\/\/doi.org\/10.1038\/s41401-024-01394-6.","journal-title":"Acta Pharmacol Sin"},{"key":"2739_CR55","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.1158\/1078-0432.CCR-17-0969","volume":"23","author":"PJ Prabakaran","year":"2017","unstructured":"Prabakaran PJ, Javaid AM, Swick AD, Werner LR, Nickel KP, Sampene E, et al. Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:6044\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0969.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2739_CR56","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41590-021-00888-3","volume":"22","author":"J Zhou","year":"2021","unstructured":"Zhou J, Kryczek I, Li S, Li X, Aguilar A, Wei S, et al. The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. Nat Immunol. 2021;22:460\u201370. https:\/\/doi.org\/10.1038\/s41590-021-00888-3.","journal-title":"Nat Immunol"},{"key":"2739_CR57","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s10565-021-09686-x","volume":"39","author":"B Sha","year":"2023","unstructured":"Sha B, Sun Y, Zhao S, Li M, Huang W, Li Z, et al. USP8 inhibitor-induced DNA damage activates cell cycle arrest, apoptosis, and autophagy in esophageal squamous cell carcinoma. Cell Biol Toxicol. 2023;39:2011\u201332. https:\/\/doi.org\/10.1007\/s10565-021-09686-x.","journal-title":"Cell Biol Toxicol"},{"key":"2739_CR58","doi-asserted-by":"publisher","first-page":"8311","DOI":"10.1039\/d4sc01294a","volume":"15","author":"L Shi","year":"2024","unstructured":"Shi L, Lu J, Xia X, Liu X, Li H, Li X, et al. Clinically used drug arsenic trioxide targets XIAP and overcomes apoptosis resistance in an organoid-based preclinical cancer model. Chem Sci. 2024;15:8311\u201322. https:\/\/doi.org\/10.1039\/d4sc01294a.","journal-title":"Chem Sci"},{"key":"2739_CR59","doi-asserted-by":"publisher","first-page":"143937","DOI":"10.1016\/j.ijbiomac.2025.143937","volume":"312","author":"K Mehdizadeh","year":"2025","unstructured":"Mehdizadeh K, Ataei F, Hosseinkhani S. Monitoring dimer structure orientation of full-length XIAP in living cells using a bioluminescence-based complementation assay. Int J Biol Macromol. 2025;312:143937. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.143937.","journal-title":"Int J Biol Macromol"},{"key":"2739_CR60","doi-asserted-by":"publisher","first-page":"e53608","DOI":"10.15252\/embr.202153608","volume":"23","author":"M Daoud","year":"2022","unstructured":"Daoud M, Broxtermann PN, Schorn F, Werthenbach JP, Seeger JM, Schiffmann LM, et al. XIAP promotes melanoma growth by inducing tumour neutrophil infiltration. EMBO Rep. 2022;23:e53608. https:\/\/doi.org\/10.15252\/embr.202153608.","journal-title":"EMBO Rep"},{"key":"2739_CR61","doi-asserted-by":"publisher","first-page":"e110468","DOI":"10.15252\/embj.2021110468","volume":"42","author":"SA Hughes","year":"2023","unstructured":"Hughes SA, Lin M, Weir A, Huang B, Xiong L, Chua NK, et al. Caspase-8-driven apoptotic and pyroptotic crosstalk causes cell death and IL-1\u03b2 release in X-linked inhibitor of apoptosis (XIAP) deficiency. EMBO J. 2023;42:e110468. https:\/\/doi.org\/10.15252\/embj.2021110468.","journal-title":"EMBO J"},{"key":"2739_CR62","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/imr.13251","volume":"321","author":"Y Xi","year":"2024","unstructured":"Xi Y, Chen L, Tang J, Yu B, Shen W, Niu X. Amplifying eat me signal by immunogenic cell death for potentiating cancer immunotherapy. Immunol Rev. 2024;321:94\u2013114. https:\/\/doi.org\/10.1111\/imr.13251.","journal-title":"Immunol Rev"},{"key":"2739_CR63","doi-asserted-by":"publisher","first-page":"7149","DOI":"10.1038\/s41467-021-27485-0","volume":"12","author":"H Li","year":"2021","unstructured":"Li H, Wang M, Huang B, Zhu S-W, Zhou J-J, Chen D-R, et al. Theranostic near-infrared-IIb emitting nanoprobes for promoting immunogenic radiotherapy and abscopal effects against cancer metastasis. Nat Commun. 2021;12:7149. https:\/\/doi.org\/10.1038\/s41467-021-27485-0.","journal-title":"Nat Commun"},{"key":"2739_CR64","doi-asserted-by":"publisher","first-page":"11429","DOI":"10.1039\/d2nr02620a","volume":"14","author":"H Song","year":"2022","unstructured":"Song H, Sun H, He N, Xu C, Wang Y, Du L, et al. Gadolinium-based ultra-small nanoparticles augment radiotherapy-induced T-cell response to synergize with checkpoint blockade immunotherapy. Nanoscale. 2022;14:11429\u201342. https:\/\/doi.org\/10.1039\/d2nr02620a.","journal-title":"Nanoscale"},{"key":"2739_CR65","doi-asserted-by":"publisher","first-page":"123281","DOI":"10.1016\/j.biomaterials.2025.123281","volume":"320","author":"M Lyu","year":"2025","unstructured":"Lyu M, Zhang T, Bao Z, Li P, Chen M, Quan H, et al. In situ forming AIEgen-alginate hydrogel for remodeling tumor microenvironment to boost FLASH immunoradiotherapy. Biomaterials. 2025;320:123281. https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123281.","journal-title":"Biomaterials"},{"key":"2739_CR66","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41420-024-02243-5","volume":"10","author":"Z Chen","year":"2024","unstructured":"Chen Z, Wang W, Hou J, Gao C, Song M, Zhao Z, et al. NEDD4L contributes to ferroptosis and cell growth inhibition in esophageal squamous cell carcinoma by facilitating xCT ubiquitination. Cell Death Discov. 2024;10:473. https:\/\/doi.org\/10.1038\/s41420-024-02243-5.","journal-title":"Cell Death Discov"},{"key":"2739_CR67","doi-asserted-by":"publisher","first-page":"124002","DOI":"10.1016\/j.biomaterials.2026.124002","volume":"330","author":"S Shin","year":"2026","unstructured":"Shin S, Bae G-H, Park JD, Koh E-Y, Ko S, Han J, et al. Transforming lipid nanoparticles into radio-activatable therapeutics through synergistic ferroptosis for enhanced cancer radiotherapy. Biomaterials. 2026;330:124002. https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124002.","journal-title":"Biomaterials"},{"key":"2739_CR68","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s13238-021-00841-y","volume":"12","author":"G Lei","year":"2021","unstructured":"Lei G, Mao C, Yan Y, Zhuang L, Gan B. Ferroptosis, radiotherapy, and combination therapeutic strategies. Protein Cell. 2021;12:836\u201357. https:\/\/doi.org\/10.1007\/s13238-021-00841-y.","journal-title":"Protein Cell"},{"key":"2739_CR69","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10555-025-10306-x","volume":"44","author":"G-X Wei","year":"2025","unstructured":"Wei G-X, Zhao Y-Q, Tang R, Shi H-S, Li Z-P. Ferroptosis at the intersection of radiotherapy and immunotherapy. Cancer Metastasis Rev. 2025;44:89. https:\/\/doi.org\/10.1007\/s10555-025-10306-x.","journal-title":"Cancer Metastasis Rev"},{"key":"2739_CR70","doi-asserted-by":"publisher","first-page":"13291","DOI":"10.1074\/jbc.R900010200","volume":"284","author":"T Nguyen","year":"2009","unstructured":"Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009;284:13291\u20135. https:\/\/doi.org\/10.1074\/jbc.R900010200.","journal-title":"J Biol Chem"},{"key":"2739_CR71","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41392-021-00793-z","volume":"6","author":"C Da","year":"2021","unstructured":"Da C, Pu J, Liu Z, Wei J, Qu Y, Wu Y, et al. HACE1-mediated NRF2 activation causes enhanced malignant phenotypes and decreased radiosensitivity of glioma cells. Signal Transduct Target Ther. 2021;6:399. https:\/\/doi.org\/10.1038\/s41392-021-00793-z.","journal-title":"Signal Transduct Target Ther"},{"key":"2739_CR72","doi-asserted-by":"publisher","first-page":"8886","DOI":"10.1158\/0008-5472.CAN-10-0171","volume":"70","author":"JT McDonald","year":"2010","unstructured":"McDonald JT, Kim K, Norris AJ, Vlashi E, Phillips TM, Lagadec C, et al. Ionizing radiation activates the Nrf2 antioxidant response. Cancer Res. 2010;70:8886\u201395. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0171.","journal-title":"Cancer Res"},{"key":"2739_CR73","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/onc.2012.189","volume":"32","author":"S Castillo-Lluva","year":"2013","unstructured":"Castillo-Lluva S, Tan C-T, Daugaard M, Sorensen PHB, Malliri A. The tumour suppressor HACE1 controls cell migration by regulating Rac1 degradation. Oncogene. 2013;32:1735\u201342. https:\/\/doi.org\/10.1038\/onc.2012.189.","journal-title":"Oncogene"},{"key":"2739_CR74","doi-asserted-by":"publisher","first-page":"e013063","DOI":"10.1136\/jitc-2025-013063","volume":"13","author":"DJ Schaer","year":"2025","unstructured":"Schaer DJ, Schulthess-Lutz N, Baselgia L, Kunasingam K, Humar R, Hansen K, et al. Stress-NRF2 response axis polarizes tumor macrophages and undermines immunotherapy. J Immunother Cancer. 2025;13:e013063. https:\/\/doi.org\/10.1136\/jitc-2025-013063.","journal-title":"J Immunother Cancer"},{"key":"2739_CR75","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1158\/1078-0432.CCR-25-0112","volume":"31","author":"R Patel","year":"2025","unstructured":"Patel R, Saab K, Luo L, Ma Y, Osman RA, Williams NT, et al. Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2025;31:4184\u201395. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0112.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2739_CR76","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1016\/j.ymthe.2024.08.019","volume":"32","author":"Y Jo","year":"2024","unstructured":"Jo Y, Shim JA, Jeong JW, Kim H, Lee SM, Jeong J, et al. Targeting ROS-sensing Nrf2 potentiates anti-tumor immunity of intratumoral CD8\u2009+\u2009T and CAR-T cells. Mol Ther J Am Soc Gene Ther. 2024;32:3879\u201394. https:\/\/doi.org\/10.1016\/j.ymthe.2024.08.019.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"2739_CR77","doi-asserted-by":"publisher","first-page":"846402","DOI":"10.3389\/fimmu.2022.846402","volume":"13","author":"Y Che","year":"2022","unstructured":"Che Y, Jiang D, Xu L, Sun Y, Wu Y, Liu Y, et al. The Clinical Prediction Value of the Ubiquitination Model Reflecting the Immune Traits in LUAD. Front Immunol. 2022;13:846402. https:\/\/doi.org\/10.3389\/fimmu.2022.846402.","journal-title":"Front Immunol"},{"key":"2739_CR78","doi-asserted-by":"publisher","first-page":"1654180","DOI":"10.3389\/fimmu.2025.1654180","volume":"16","author":"X Lin","year":"2025","unstructured":"Lin X, Zhao S, Li L, Huang Y, Zhong Q, Luo H, et al. Prognostic model of ubiquitination-related genes in ovarian cancer based on transcriptomic analysis and experimental validation. Front Immunol. 2025;16:1654180. https:\/\/doi.org\/10.3389\/fimmu.2025.1654180.","journal-title":"Front Immunol"},{"key":"2739_CR79","doi-asserted-by":"publisher","first-page":"11787","DOI":"10.1038\/s41598-025-92177-4","volume":"15","author":"D Sun","year":"2025","unstructured":"Sun D, Duan X, Li N, Qiao O, Hou Y, Ma Z, et al. Construction of ubiquitination-related risk model for predicting prognosis in lung adenocarcinoma. Sci Rep. 2025;15:11787. https:\/\/doi.org\/10.1038\/s41598-025-92177-4.","journal-title":"Sci Rep"},{"key":"2739_CR80","doi-asserted-by":"publisher","first-page":"1171811","DOI":"10.3389\/fimmu.2023.1171811","volume":"14","author":"Y Guo","year":"2023","unstructured":"Guo Y, Wu Z, Cen K, Bai Y, Dai Y, Mai Y, et al. Establishment and validation of a ubiquitination-related gene signature associated with prognosis in pancreatic duct adenocarcinoma. Front Immunol. 2023;14:1171811. https:\/\/doi.org\/10.3389\/fimmu.2023.1171811.","journal-title":"Front Immunol"},{"key":"2739_CR81","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ymthe.2025.01.047","volume":"33","author":"J Shi","year":"2025","unstructured":"Shi J, Zhang Z, Chen H-Y, Yao Y, Ke S, Yu K, et al. Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy. Mol Ther J Am Soc Gene Ther. 2025;33:1073\u201390. https:\/\/doi.org\/10.1016\/j.ymthe.2025.01.047.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"2739_CR82","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.apsb.2025.10.039","volume":"16","author":"X Wang","year":"2026","unstructured":"Wang X, Zhao Y, Yang X, Liu T, Zhou W, Niu S, et al. Radiation-induced nuclear translocation of NPRL2 hijacks E3 ubiquitin ligases to enhance DNA repair via the AMPK\/WDR24 axis, contributing to CRC radioresistance. Acta Pharm Sin B. 2026;16:252\u201369. https:\/\/doi.org\/10.1016\/j.apsb.2025.10.039.","journal-title":"Acta Pharm Sin B"},{"key":"2739_CR83","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/2159-8290.CD-19-1416","volume":"10","author":"C Gstalder","year":"2020","unstructured":"Gstalder C, Liu D, Miao D, Lutterbach B, DeVine AL, Lin C, et al. Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discov. 2020;10:1296\u2013311. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1416.","journal-title":"Cancer Discov"},{"key":"2739_CR84","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618. https:\/\/doi.org\/10.1038\/ncomms15618.","journal-title":"Nat Commun"},{"key":"2739_CR85","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamaoncol.2023.2132","volume":"9","author":"M Spaas","year":"2023","unstructured":"Spaas M, Sundahl N, Kruse V, Rottey S, De Maeseneer D, Duprez F, et al. Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023;9:1205. https:\/\/doi.org\/10.1001\/jamaoncol.2023.2132.","journal-title":"JAMA Oncol"},{"key":"2739_CR86","doi-asserted-by":"publisher","unstructured":"Xiu Z, Sun T, Yang Y, He Y, Yang S, Xue X et al. B <>Wang editor 2022 Curcumin Enhanced Ionizing Radiation-Induced Immunogenic Cell Death in Glioma Cells through Endoplasmic Reticulum Stress Signaling Pathways. Oxid Med Cell Longev 2022 5424411 https:\/\/doi.org\/10.1155\/2022\/5424411.","DOI":"10.1155\/2022\/5424411"},{"key":"2739_CR87","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1038\/s41586-019-1351-8","volume":"571","author":"J Zhang","year":"2019","unstructured":"Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, et al. Author Correction: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2019;571:E10. https:\/\/doi.org\/10.1038\/s41586-019-1351-8.","journal-title":"Nature"},{"key":"2739_CR88","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00018-024-05144-z","volume":"81","author":"Z Yu","year":"2024","unstructured":"Yu Z, Wu X, Zhu J, Yan H, Li Y, Zhang H, et al. BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma. Cell Mol Life Sci. 2024;81:82. https:\/\/doi.org\/10.1007\/s00018-024-05144-z.","journal-title":"Cell Mol Life Sci"},{"key":"2739_CR89","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41418-022-01097-7","volume":"30","author":"K Gao","year":"2023","unstructured":"Gao K, Shi Q, Gu Y, Yang W, He Y, Lv Z, et al. SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1\u2013PD-L1 axis. Cell Death Differ. 2023;30:475\u201387. https:\/\/doi.org\/10.1038\/s41418-022-01097-7.","journal-title":"Cell Death Differ"},{"key":"2739_CR90","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41422-025-01205-5","volume":"36","author":"Q Zhao","year":"2026","unstructured":"Zhao Q, Li C, Zhang M, Gao T, Wang Z, Li Z, et al. Tumor PD-L1 induces \u03b22m ubiquitylation and degradation for cancer cell immune evasion. Cell Res. 2026;36:38\u201350. https:\/\/doi.org\/10.1038\/s41422-025-01205-5.","journal-title":"Cell Res"},{"key":"2739_CR91","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1016\/j.cell.2023.07.016","volume":"186","author":"X Chen","year":"2023","unstructured":"Chen X, Lu Q, Zhou H, Liu J, Nadorp B, Lasry A, et al. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell. 2023;186:3903\u2013e392021. https:\/\/doi.org\/10.1016\/j.cell.2023.07.016.","journal-title":"Cell"},{"key":"2739_CR92","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3390\/cells12121653","volume":"12","author":"J Fleischmann","year":"2023","unstructured":"Fleischmann J, Hildebrand LS, Kuhlmann L, Fietkau R, Distel LV. The Effect of Xevinapant Combined with Ionizing Radiation on HNSCC and Normal Tissue Cells and the Impact of Xevinapant on Its Targeted Proteins cIAP1 and XIAP. Cells. 2023;12:1653. https:\/\/doi.org\/10.3390\/cells12121653.","journal-title":"Cells"},{"key":"2739_CR93","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13046-025-03452-1","volume":"44","author":"Q Wu","year":"2025","unstructured":"Wu Q, Chen J, Berglund AE, Du D, Macaulay RJ, Etame AB. The reprogramming impact of SMAC-mimetic on glioblastoma stem cells and the immune tumor microenvironment evolution. J Exp Clin Cancer Res. 2025;44:191. https:\/\/doi.org\/10.1186\/s13046-025-03452-1.","journal-title":"J Exp Clin Cancer Res"},{"key":"2739_CR94","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2022.12.015","volume":"183","author":"Y Tao","year":"2023","unstructured":"Tao Y, Sun X-S, Pointreau Y, Le Tourneau C, Sire C, Kaminsky M-C, et al. Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial. Eur J Cancer. 2023;183:24\u201337. https:\/\/doi.org\/10.1016\/j.ejca.2022.12.015.","journal-title":"Eur J Cancer"},{"key":"2739_CR95","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/cpt.3065","volume":"115","author":"Y Vugmeyster","year":"2024","unstructured":"Vugmeyster Y, Ravula A, Rouits E, Diderichsen PM, Kleijn HJ, Koenig A, et al. Model-Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Clin Pharmacol Ther. 2024;115:52\u201361. https:\/\/doi.org\/10.1002\/cpt.3065.","journal-title":"Clin Pharmacol Ther"},{"key":"2739_CR96","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1200\/JCO-25-00272","volume":"43","author":"J Bourhis","year":"2025","unstructured":"Bourhis J, Licitra LF, Burtness B, Psyrri A, Haddad R, Harrington K, et al. Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. J Clin Oncol. 2025;43:3209\u201320. https:\/\/doi.org\/10.1200\/JCO-25-00272.","journal-title":"J Clin Oncol"},{"key":"2739_CR97","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1158\/1078-0432.CCR-25-0429","volume":"31","author":"NC Schmitt","year":"2025","unstructured":"Schmitt NC, Stokes WA, Bates JE, Kinney BLC, Remick J, McDonald MW, et al. Early-Phase Trial of IAP Antagonist Tolinapant and Definitive Radiation in Cisplatin-Ineligible Patients with Advanced Head and Neck Cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2025;31:2910\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0429.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2739_CR98","doi-asserted-by":"publisher","first-page":"1179827","DOI":"10.3389\/fimmu.2023.1179827","volume":"14","author":"A Afsahi","year":"2023","unstructured":"Afsahi A, Silvestri CM, Moore AE, Graham CF, Bacchiochi K, St-Jean M, et al. LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling. Front Immunol. 2023;14:1179827. https:\/\/doi.org\/10.3389\/fimmu.2023.1179827.","journal-title":"Front Immunol"},{"key":"2739_CR99","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/oncolo\/oyad029","volume":"28","author":"ML Johnson","year":"2023","unstructured":"Johnson ML, Patel MR, Aljumaily R, Jones SF, Burris Iii HA, Spigel DR. A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed\/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies. Oncologist. 2023;28:640\u2013e559. https:\/\/doi.org\/10.1093\/oncolo\/oyad029.","journal-title":"Oncologist"},{"key":"2739_CR100","doi-asserted-by":"publisher","first-page":"103636","DOI":"10.1016\/j.esmoop.2024.103636","volume":"9","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wen X, Peng R, Pan Q, Weng D, Ma Y, et al. A first-in-human phase I study of a novel MDM2\/p53 inhibitor alrizomadlin in advanced solid tumors. ESMO Open. 2024;9:103636. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103636.","journal-title":"ESMO Open"},{"key":"2739_CR101","unstructured":"Reijers ILM, Menzies AM, Versluis JM, Saw RPM, van Houdt WJ, Kapiteijn E et al. The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo."},{"key":"2739_CR102","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s40425-019-0750-6","volume":"7","author":"DD Fang","year":"2019","unstructured":"Fang DD, Tang Q, Kong Y, Wang Q, Gu J, Fang X, et al. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. J Immunother Cancer. 2019;7:327. https:\/\/doi.org\/10.1186\/s40425-019-0750-6.","journal-title":"J Immunother Cancer"},{"key":"2739_CR103","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.22.01285","volume":"41","author":"MM Gounder","year":"2023","unstructured":"Gounder MM, Bauer TM, Schwartz GK, Weise AM, LoRusso P, Kumar P, et al. A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41:1714\u201324. https:\/\/doi.org\/10.1200\/JCO.22.01285.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2739_CR104","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1158\/1078-0432.CCR-21-1295","volume":"28","author":"EM Stein","year":"2022","unstructured":"Stein EM, DeAngelo DJ, Chromik J, Chatterjee M, Bauer S, Lin C-C, et al. Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28:870\u201381. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1295.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2739_CR105","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1182\/blood.2022016082","volume":"140","author":"JNHG Ho","year":"2022","unstructured":"Ho JNHG, Schmidt D, Lowinus T, Ryoo J, Dopfer E-P, Gonzalo N\u00fa\u00f1ez N, et al. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1\/2 upregulation. Blood. 2022;140:1167\u201381. https:\/\/doi.org\/10.1182\/blood.2022016082.","journal-title":"Blood"},{"key":"2739_CR106","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/pbc.25465","volume":"62","author":"D Phelps","year":"2015","unstructured":"Phelps D, Bondra K, Seum S, Chronowski C, Leasure J, Kurmasheva RT, et al. Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma. Pediatr Blood Cancer. 2015;62:1345\u201352. https:\/\/doi.org\/10.1002\/pbc.25465.","journal-title":"Pediatr Blood Cancer"},{"key":"2739_CR107","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s10495-024-02014-8","volume":"29","author":"NV Pervushin","year":"2024","unstructured":"Pervushin NV, Nilov DK, Pushkarev SV, Shipunova VO, Badlaeva AS, Yapryntseva MA, et al. BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition. Apoptosis Int J Program Cell Death. 2024;29:2197\u2013213. https:\/\/doi.org\/10.1007\/s10495-024-02014-8.","journal-title":"Apoptosis Int J Program Cell Death"},{"key":"2739_CR108","doi-asserted-by":"publisher","first-page":"102217","DOI":"10.1016\/j.esmoop.2023.102217","volume":"9","author":"B Perez","year":"2024","unstructured":"Perez B, Aljumaily R, Marron TU, Shafique MR, Burris H, Iams WT, et al. Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors. ESMO Open. 2024;9:102217. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102217.","journal-title":"ESMO Open"},{"key":"2739_CR109","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/1541-7786.MCR-21-0612","volume":"20","author":"MI Carr","year":"2022","unstructured":"Carr MI, Chiu L-Y, Guo Y, Xu C, Lazorchak AS, Yu H, et al. DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGF\u03b2\/PD-L1 Targeted Cancer Immunotherapy. Mol Cancer Res MCR. 2022;20:568\u201382. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0612.","journal-title":"Mol Cancer Res MCR"},{"key":"2739_CR110","doi-asserted-by":"publisher","first-page":"12148","DOI":"10.1038\/s41598-021-90500-3","volume":"11","author":"E Haines","year":"2021","unstructured":"Haines E, Nishida Y, Carr MI, Montoya RH, Ostermann LB, Zhang W, et al. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia. Sci Rep. 2021;11:12148. https:\/\/doi.org\/10.1038\/s41598-021-90500-3.","journal-title":"Sci Rep"},{"key":"2739_CR111","doi-asserted-by":"publisher","first-page":"31102","DOI":"10.1074\/jbc.M114.594283","volume":"289","author":"ML Schmidt","year":"2014","unstructured":"Schmidt ML, Donninger H, Clark GJ. Ras regulates SCF(\u03b2-TrCP) protein activity and specificity via its effector protein NORE1A. J Biol Chem. 2014;289:31102\u201310. https:\/\/doi.org\/10.1074\/jbc.M114.594283.","journal-title":"J Biol Chem"},{"key":"2739_CR112","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1172\/JCI71602","volume":"124","author":"NM Weathington","year":"2014","unstructured":"Weathington NM, Mallampalli RK. Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest. 2014;124:6\u201312. https:\/\/doi.org\/10.1172\/JCI71602.","journal-title":"J Clin Invest"},{"key":"2739_CR113","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1021\/ja039025z","volume":"126","author":"JS Schneekloth","year":"2004","unstructured":"Schneekloth JS, Fonseca FN, Koldobskiy M, Mandal A, Deshaies R, Sakamoto K, et al. Chemical genetic control of protein levels: selective in vivo targeted degradation. J Am Chem Soc. 2004;126:3748\u201354. https:\/\/doi.org\/10.1021\/ja039025z.","journal-title":"J Am Chem Soc"},{"key":"2739_CR114","doi-asserted-by":"publisher","first-page":"eado6492","DOI":"10.1126\/sciadv.ado6492","volume":"10","author":"C Crowe","year":"2024","unstructured":"Crowe C, Nakasone MA, Chandler S, Craigon C, Sathe G, Tatham MH, et al. Mechanism of degrader-targeted protein ubiquitinability. Sci Adv. 2024;10:eado6492. https:\/\/doi.org\/10.1126\/sciadv.ado6492.","journal-title":"Sci Adv"},{"key":"2739_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15384047.2022.2125748","volume":"23","author":"L Ma","year":"2022","unstructured":"Ma L, Wang J, Zhang Y, Fang F, Ling J, Chu X, et al. BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes. Cancer Biol Ther. 2022;23:1\u201315. https:\/\/doi.org\/10.1080\/15384047.2022.2125748.","journal-title":"Cancer Biol Ther"},{"key":"2739_CR116","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","volume":"30","author":"SM Gough","year":"2024","unstructured":"Gough SM, Flanagan JJ, Teh J, Andreoli M, Rousseau E, Pannone M, et al. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4\/6 or PI3K\/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clin Cancer Res Off J Am Assoc Cancer Res. 2024;30:3549\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3465.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2739_CR117","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2505725","volume":"393","author":"M Campone","year":"2025","unstructured":"Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, et al. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. N Engl J Med. 2025;393:556\u201368. https:\/\/doi.org\/10.1056\/NEJMoa2505725.","journal-title":"N Engl J Med"},{"key":"2739_CR118","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","volume":"24","author":"LB Snyder","year":"2025","unstructured":"Snyder LB, Neklesa TK, Willard RR, Gordon DA, Pizzano J, Vitale N, et al. Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader. Mol Cancer Ther. 2025;24:511\u201322. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0655.","journal-title":"Mol Cancer Ther"},{"key":"2739_CR119","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938\u201347. https:\/\/doi.org\/10.1038\/s41591-019-0668-z.","journal-title":"Nat Med"},{"key":"2739_CR120","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1182\/blood-2024-210301","volume":"144","author":"T Feldman","year":"2024","unstructured":"Feldman T, Marchi E, Smith SD, Olszewski AJ, Huen AO, Epstein-Peterson ZD, et al. Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors. Blood. 2024;144:4433\u20134433. https:\/\/doi.org\/10.1182\/blood-2024-210301.","journal-title":"Blood"},{"key":"2739_CR121","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev-pharmtox-022123-104147","volume":"64","author":"V Oleinikovas","year":"2024","unstructured":"Oleinikovas V, Gainza P, Ryckmans T, Fasching B, Thom\u00e4 NH. From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation. Annu Rev Pharmacol Toxicol. 2024;64:291\u2013312. https:\/\/doi.org\/10.1146\/annurev-pharmtox-022123-104147.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2739_CR122","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","volume":"512","author":"ES Fischer","year":"2014","unstructured":"Fischer ES, B\u00f6hm K, Lydeard JR, Yang H, Stadler MB, Cavadini S, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014;512:49\u201353. https:\/\/doi.org\/10.1038\/nature13527.","journal-title":"Nature"},{"key":"2739_CR123","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","volume":"389","author":"PG Richardson","year":"2023","unstructured":"Richardson PG, Trudel S, Popat R, Mateos M-V, Vangsted AJ, Ramasamy K, et al. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023;389:1009\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2303194.","journal-title":"N Engl J Med"},{"key":"2739_CR124","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","volume":"184","author":"SX Lu","year":"2021","unstructured":"Lu SX, De Neef E, Thomas JD, Sabio E, Rousseau B, Gigoux M, et al. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell. 2021;184:4032\u2013e404731. https:\/\/doi.org\/10.1016\/j.cell.2021.05.038.","journal-title":"Cell"},{"key":"2739_CR125","doi-asserted-by":"publisher","first-page":"113307","DOI":"10.1016\/j.celrep.2023.113307","volume":"42","author":"Y Xu","year":"2023","unstructured":"Xu Y, Spear S, Ma Y, Lorentzen MP, Gruet M, McKinney F, et al. Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. Cell Rep. 2023;42:113307. https:\/\/doi.org\/10.1016\/j.celrep.2023.113307.","journal-title":"Cell Rep"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02739-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02739-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02739-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:26:41Z","timestamp":1788942401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02739-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":125,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2739"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02739-x","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"212"}}